Biotech Startups

Avivo develops enzyme-based technology to convert blood types and enable organ compatibility, increasing access to transfusions and transplants while reducing waste in healthcare systems. The company serves hospitals, transplant centers, military and emergency care settings with a platform designed to integrate into existing clinical workflows.

1 investor

Avotres is a biopharmaceutical company developing therapeutics targeting autoimmune diseases and cancer. Its work centers on a pipeline of drug candidates addressing immune-related conditions.

1 investor

AVROBIO develops ex vivo lentiviral vector-based hematopoietic stem cell gene therapies to treat lysosomal disorders by permanently integrating therapeutic genes into patient stem cells manufactured outside the body. The modified cells differentiate into multiple cell types capable of crossing the blood-brain barrier to deliver treatment throughout the body and central nervous system.

1 investor

AVS Bio raises Specific Pathogen Free (SPF) chickens in US-based biosecurity facilities for use in vaccine manufacturing, quality control testing, and research applications. The company supplies pathogen-free birds of various ages to pharmaceutical, biotech, and research organizations requiring controlled biological systems for regulatory and scientific work.

1 investor

Avvio AMEA develops kidney stone treatment technology for urological care, targeting patients and healthcare providers across Asia, the Middle East, and Africa. It is the regional arm of Avvio Medical, whose investigational medical device has not yet received regulatory clearance.

1 investor

Acoustic Wave Cell Therapy develops an acoustic wave-based investigational medical device, currently limited to investigational use under U.S. federal law. The company operates in the urology and medical device field, with a focus related to treatment of conditions such as erectile dysfunction.

1 investor

Awen Oncology is a drug discovery company developing first-in-class oncology therapeutics that target cancer-specific proteins found only in tumor cells, aiming for treatments with improved efficacy and fewer side effects. It combines high-throughput cell and molecular biology with computational techniques to identify novel therapeutic targets for cancer patients.

1 investor

A life sciences company offering nanopore sequencing instruments and automated library preparation systems for molecular biology research.

1 investor

Axcelead is a healthcare platform company with drug discovery as its core business, supporting pharmaceutical research for biotech ventures, pharmaceutical companies, and academic institutions. The company provides comprehensive drug discovery solutions leveraging advanced screening systems, compound libraries, and experienced researchers.

1 investor

Axelia Oncology is a biopharmaceutical company developing AXA-042, a selective immunological agent designed to activate innate immune responses against checkpoint-insensitive solid tumors. The company focuses on oncology therapeutics through activation of TLR2/6 pathways.

1 investor

Axelyf develops RNA medicines built on nanotechnology formulations and nucleic acid technologies, working across the drug development pathway from CMC and clinical pharmacology to computational sciences. The company focuses on RNA therapeutics platform development and associated therapeutic programs.

1 investor

Axent Biosciences develops stem cell therapies to treat diseases like Parkinson's, using a proprietary cell cultivation platform to enable scalable and cost-effective manufacturing. The company was spun out of UC Berkeley research and aims to make stem cell therapies broadly accessible.

1 investor

Axial Orthopaedics is a medtech company in orthopedic healthcare, with leadership experienced in strategic exits.

1 investor

Axia is a vegetable seed breeding company that develops high-quality tomato and vegetable varieties for greenhouse cultivation, both heated and unheated, with or without artificial light. The company focuses on taste, quality, and yield through state-of-the-art research and development, serving growers and supply chain partners globally.

1 investor

Axiota develops an animal health platform focused on cattle products designed to help cattle thrive during transition and stress periods, serving cattle producers and consumers.

1 investor

1 investor

Axxam develops AXXSense, a cell-based platform for assessing taste and olfactory properties of pharmaceutical compounds during drug development. The platform uses human bitter taste receptors and trigeminal assays to predict bitterness and off-tastes early in the pipeline, helping pharmaceutical companies optimize formulations and reduce late-stage reformulation risks.

1 investor

Biopharmaceutical company that went public on NASDAQ in 2021 (AADI)

1 investor

Ayuvant is developing an RNA-nanoparticle immunotherapy designed to direct the immune system to recognize and attack cancer cells. The platform targets patients who do not respond to existing immune checkpoint inhibitors and has shown antitumor activity in checkpoint-inhibitor-resistant models.

1 investor

Azane Therapeutics is a therapeutics company focused on nucleic acid delivery.

1 investor

AZBio is a statewide industry association and advocate for Arizona's bioscience sector, connecting biotech, medtech, and healthcare organizations to support the state's life science ecosystem. The organization provides resources, leadership, and advocacy to establish Arizona as a top-ten life science state.

1 investor

Azevan Pharmaceuticals is a clinical-stage biopharmaceutical company developing orally bioavailable V1a receptor antagonists targeting vasopressin biology for neuropsychiatric, neurodegenerative, neurodevelopmental, and brain injury conditions. The company's lead candidate SRX246 has shown efficacy in reducing pathological aggression in Huntington's Disease and Intermittent Explosive Disorder.

1 investor

1 investor

Azkarra Therapeutics develops small molecule drugs targeting DNA damage repair and immune response pathways for cancer and inflammatory diseases. The company focuses on novel PARP inhibitors, PARG inhibitors, and OGG1 inhibitors as next-generation precision therapeutics.

1 investor